Jeffrey S. Schechner
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jeffrey S. Schechner has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
Alfred L. M. Bothwell
Departments of Immunobiology Yale University School of Medicine New Haven Connecticut USA
2 shared publicationsFeiya Wang
2 shared publicationsGeorge Tellides
Departments of Surgery Yale University School of Medicine New Haven Connecticut USA
2 shared publicationsJordan S. Pober
Departments of Dermatology Yale University School of Medicine New Haven Connecticut USA
2 shared publications- Jordan S. Pober
Dept of Immunobiology, Yale University School of Medicine, New Haven, CT, USA
2 shared publications Marc I. Lorber
Departments of Surgery Yale University School of Medicine New Haven Connecticut USA
2 shared publications
Latest Publications
- 1 February 2008
- Published by Wolters Kluwer Health in Dermatologic Surgery
- Vol. 34 (2) , 137-146
In Vivo Perfusion of Human Skin Substitutes With Microvessels Formed by Adult Circulating Endothelial Progenitor Cells
- 1 February 2008
- Published by Wolters Kluwer Health in Dermatologic Surgery
- Vol. 34 (2) , 137-146
In Vivo Perfusion of Human Skin Substitutes With Microvessels Formed by Adult Circulating Endothelial Progenitor Cells
- Open Access
- 16 March 2004
- Published by Springer Nature in BMC Immunology
- Vol. 5 (1) , 5
Endothelial cells present antigens in vivo
Immune recognition of vascular endothelial cells (EC) has been implicated in allograft rejection, protection against pathogens, and lymphocyte recruitment. However, EC pervade nearly all tissues and predominate in none, complicating any direct test of immune recognition. Here, we examined antigen presentation by EC in vivo by testing immune responses against E. coli beta-galactosidase (beta-gal) in two lines of transgenic mice that express beta-gal exclusively in their EC. TIE2-lacZ mice express beta-gal in all EC and VWF-lacZ mice express beta-gal in heart and brain microvascular EC. Transgenic and congenic wild type FVB mice immunized with beta-gal expression vector DNA or beta-gal protein generated high titer, high affinity antisera containing comparable levels of antigen-specific IgG1 and IgG2a isotypes, suggesting equivalent activation of T helper cell subsets. The immunized transgenic mice remained healthy, their EC continued to express beta-gal, and their blood vessels showed no histological abnormalities. In response to beta-gal in vitro, CD4+ and CD8+ T cells from immunized transgenic and FVB mice proliferated, expressed CD25, and secreted IFN-gamma. Infection with recombinant vaccinia virus encoding beta-gal raised equivalent responses in transgenic and FVB mice. Hearts transplanted from transgenic mice into FVB mice continued to beat and the graft EC continued to express beta-gal. These results suggested immunological ignorance of the transgene encoded EC protein. However, skin transplanted from TIE2-lacZ onto FVB mice lost beta-gal+ EC and the hosts developed beta-gal-specific antisera, demonstrating activation of host immune effector mechanisms. In contrast, skin grafted from TIE2-lacZ onto VWF-lacZ mice retained beta-gal+ EC and no antisera developed, suggesting a tolerant host immune system. Resting, beta-gal+ EC in transgenic mice tolerize specific lymphocytes that would otherwise respond against beta-gal expressed by EC within transplanted skin. We conclude that EC effectively present intracellular "self" proteins to the immune system. However, antigen presentation by EC does not delete or anergize a large population of specific lymphocytes that respond to the same protein following conventional immunization with protein or expression vector DNA. These results clearly demonstrate striking context sensitivity in the immune recognition of EC, a subtlety that must be better understood in order to treat immune diseases and complications involving the vasculature.
- 16 March 2004
- Published by Springer Nature in BMC Immunology
- Vol. 5 (1) , 5
Open AccessEndothelial cells present antigens in vivo
Immune recognition of vascular endothelial cells (EC) has been implicated in allograft rejection, protection against pathogens, and lymphocyte recruitment. However, EC pervade nearly all tissues and predominate in none, complicating any direct test of immune recognition. Here, we examined antigen presentation by EC in vivo by testing immune responses against E. coli beta-galactosidase (beta-gal) in two lines of transgenic mice that express beta-gal exclusively in their EC. TIE2-lacZ mice express beta-gal in all EC and VWF-lacZ mice express beta-gal in heart and brain microvascular EC. Transgenic and congenic wild type FVB mice immunized with beta-gal expression vector DNA or beta-gal protein generated high titer, high affinity antisera containing comparable levels of antigen-specific IgG1 and IgG2a isotypes, suggesting equivalent activation of T helper cell subsets. The immunized transgenic mice remained healthy, their EC continued to express beta-gal, and their blood vessels showed no histological abnormalities. In response to beta-gal in vitro, CD4+ and CD8+ T cells from immunized transgenic and FVB mice proliferated, expressed CD25, and secreted IFN-gamma. Infection with recombinant vaccinia virus encoding beta-gal raised equivalent responses in transgenic and FVB mice. Hearts transplanted from transgenic mice into FVB mice continued to beat and the graft EC continued to express beta-gal. These results suggested immunological ignorance of the transgene encoded EC protein. However, skin transplanted from TIE2-lacZ onto FVB mice lost beta-gal+ EC and the hosts developed beta-gal-specific antisera, demonstrating activation of host immune effector mechanisms. In contrast, skin grafted from TIE2-lacZ onto VWF-lacZ mice retained beta-gal+ EC and no antisera developed, suggesting a tolerant host immune system. Resting, beta-gal+ EC in transgenic mice tolerize specific lymphocytes that would otherwise respond against beta-gal expressed by EC within transplanted skin. We conclude that EC effectively present intracellular "self" proteins to the immune system. However, antigen presentation by EC does not delete or anergize a large population of specific lymphocytes that respond to the same protein following conventional immunization with protein or expression vector DNA. These results clearly demonstrate striking context sensitivity in the immune recognition of EC, a subtlety that must be better understood in order to treat immune diseases and complications involving the vasculature.
- Open Access
- 1 December 2003
- Published by Wiley in The FASEB Journal
- Vol. 17 (15) , 2250-2256
Engraftment of a vascularized human skin equivalent
Clinical performance of currently avail able human skin equivalents is limited by failure to develop perfusion. To address this problem we have developed a method of endothelial cell transplantation that promotes vascularization of human skin equiva lents in vivo. Enhancement of vascularization by Bcl‐2 overexpression was demonstrated by seeding human acellular dermis grafts with human umbilical vein en dothelial cells (HUVEC) transduced with the survival gene Bcl‐2 or an EGFP control transgene, and subcuta neous implantation in immunodeficient mice ( n =18). After 1 month the grafts with Bcl‐2‐transduced cells contained a significantly greater density of perfused HUVEC‐lined microvessels (55.0/mm 3 ) than controls (25.4/mm 3 , P =0.026). Vascularized skin equivalents were then constructed by sequentially seeding the api cal and basal surfaces of acellular dermis with cultured human keratinocytes and Bcl‐2‐transduced HUVEC, respectively. Two weeks after orthotopic implantation onto mice, 75% of grafts ( n =16) displayed both a differentiated human epidermis and perfusion through HUVEC‐lined microvessels. These vessels, which showed evidence of progressive maturation, acceler ated the rate of graft vascularization. Successful trans plantation of such vascularized human skin equivalents should enhance clinical utility, especially in recipients with impaired angiogenesis.—Schechner, J. S., Crane, S. K., Wang, F., Szeglin, A. M., Tellides, G., Lorber, M. I., Bothwell, A. L. M., Pober, J. S. Engraftment of a vascularized human skin equivalent. FASEB J. 17, 2250‐2256 (2003)
- 1 December 2003
- Published by Wiley in The FASEB Journal
- Vol. 17 (15) , 2250-2256
Open AccessEngraftment of a vascularized human skin equivalent
Clinical performance of currently avail able human skin equivalents is limited by failure to develop perfusion. To address this problem we have developed a method of endothelial cell transplantation that promotes vascularization of human skin equiva lents in vivo. Enhancement of vascularization by Bcl‐2 overexpression was demonstrated by seeding human acellular dermis grafts with human umbilical vein en dothelial cells (HUVEC) transduced with the survival gene Bcl‐2 or an EGFP control transgene, and subcuta neous implantation in immunodeficient mice ( n =18). After 1 month the grafts with Bcl‐2‐transduced cells contained a significantly greater density of perfused HUVEC‐lined microvessels (55.0/mm 3 ) than controls (25.4/mm 3 , P =0.026). Vascularized skin equivalents were then constructed by sequentially seeding the api cal and basal surfaces of acellular dermis with cultured human keratinocytes and Bcl‐2‐transduced HUVEC, respectively. Two weeks after orthotopic implantation onto mice, 75% of grafts ( n =16) displayed both a differentiated human epidermis and perfusion through HUVEC‐lined microvessels. These vessels, which showed evidence of progressive maturation, acceler ated the rate of graft vascularization. Successful trans plantation of such vascularized human skin equivalents should enhance clinical utility, especially in recipients with impaired angiogenesis.—Schechner, J. S., Crane, S. K., Wang, F., Szeglin, A. M., Tellides, G., Lorber, M. I., Bothwell, A. L. M., Pober, J. S. Engraftment of a vascularized human skin equivalent. FASEB J. 17, 2250‐2256 (2003)
- Open Access
- 11 July 2000
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 97 (16) , 9191-9196
In vivo formation of complex microvessels lined by human endothelial cells in an immunodeficient mouse
We have identified conditions for forming cultured human umbilical vein endothelial cells (HUVEC) into tubes within a three-dimensional gel that on implantation into immunoincompetent mice undergo remodeling into complex microvessels lined by human endothelium. HUVEC suspended in mixed collagen/fibronectin gels organize into cords with early lumena by 24 h and then apoptose. Twenty-hour constructs, s.c. implanted in immunodeficient mice, display HUVEC-lined thin-walled microvessels within the gel 31 days after implantation. Retroviral-mediated overexpression of a caspase-resistant Bcl-2 protein delays HUVEC apoptosis in vitro for over 7 days. Bcl-2-transduced HUVEC produce an increased density of HUVEC-lined perfused microvessels in vivo compared with untransduced or control-transduced HUVEC. Remarkably, Bcl-2- but not control-transduced HUVEC recruit an ingrowth of perivascular smooth-muscle α-actin-expressing mouse cells at 31 days, which organize by 60 days into HUVEC-lined multilayered structures resembling true microvessels. This system provides an in vivo model for dissecting mechanisms of microvascular remodeling by using genetically modified endothelium. Incorporation of such human endothelial-lined microvessels into engineered synthetic skin may improve graft viability, especially in recipients with impaired angiogenesis.
- 11 July 2000
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 97 (16) , 9191-9196
Open AccessIn vivo formation of complex microvessels lined by human endothelial cells in an immunodeficient mouse
We have identified conditions for forming cultured human umbilical vein endothelial cells (HUVEC) into tubes within a three-dimensional gel that on implantation into immunoincompetent mice undergo remodeling into complex microvessels lined by human endothelium. HUVEC suspended in mixed collagen/fibronectin gels organize into cords with early lumena by 24 h and then apoptose. Twenty-hour constructs, s.c. implanted in immunodeficient mice, display HUVEC-lined thin-walled microvessels within the gel 31 days after implantation. Retroviral-mediated overexpression of a caspase-resistant Bcl-2 protein delays HUVEC apoptosis in vitro for over 7 days. Bcl-2-transduced HUVEC produce an increased density of HUVEC-lined perfused microvessels in vivo compared with untransduced or control-transduced HUVEC. Remarkably, Bcl-2- but not control-transduced HUVEC recruit an ingrowth of perivascular smooth-muscle α-actin-expressing mouse cells at 31 days, which organize by 60 days into HUVEC-lined multilayered structures resembling true microvessels. This system provides an in vivo model for dissecting mechanisms of microvascular remodeling by using genetically modified endothelium. Incorporation of such human endothelial-lined microvessels into engineered synthetic skin may improve graft viability, especially in recipients with impaired angiogenesis.
- 1 March 1999
- Published by SAGE Publications in Diabetes Technology & Therapeutics
- Vol. 1 (1) , 39-40
Blood Glucose Monitoring in the Cutaneous Microenvironment
- 1 March 1999
- Published by SAGE Publications in Diabetes Technology & Therapeutics
- Vol. 1 (1) , 39-40
Blood Glucose Monitoring in the Cutaneous Microenvironment
- 31 March 1998
- Published by Elsevier in Journal of Dermatological Science
- Vol. 16, S168
Expression of integrin α4β7 on epidermotropic cutaneous T cells in cutaneous T cell lymphoma and spongiotic dermatitis
- 31 March 1998
- Published by Elsevier in Journal of Dermatological Science
- Vol. 16, S168
Expression of integrin α4β7 on epidermotropic cutaneous T cells in cutaneous T cell lymphoma and spongiotic dermatitis